219 related articles for article (PubMed ID: 36803278)
21. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
22. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
Bose CK
Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
[TBL] [Abstract][Full Text] [Related]
23. Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy in Cervical Cancer.
Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials.
Xing Y; Yasinjan F; Du Y; Geng H; Zhang Y; He M; Guo R; Yang L; Cui J; Mu D; Liu Z; Wang H
Front Immunol; 2023; 14():1094437. PubMed ID: 36817443
[TBL] [Abstract][Full Text] [Related]
26. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
27. Advances in paclitaxel combinations for treating cervical cancer.
Della Corte L; Barra F; Foreste V; Giampaolino P; Evangelisti G; Ferrero S; Bifulco G
Expert Opin Pharmacother; 2020 Apr; 21(6):663-677. PubMed ID: 32037907
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
[TBL] [Abstract][Full Text] [Related]
29. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data.
Song Z; Zou K; Zou L
Front Oncol; 2022; 12():1045481. PubMed ID: 36644634
[TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapy of cervical cancer.
Legge F; Fuoco G; Lorusso D; Lucidi A; Borriello M; Pisconti S; Scambia G; Ferrandina G
Expert Opin Pharmacother; 2010 Aug; 11(12):2059-75. PubMed ID: 20642372
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
33. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Tolcher A; Hamilton E; Coleman RL
Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy for metastatic and recurrent cervical cancer.
Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
[TBL] [Abstract][Full Text] [Related]
35. Bladder cancer: shedding light on the most promising investigational drugs in clinical trials.
Bin Riaz I; Khan AM; Catto JW; Hussain SA
Expert Opin Investig Drugs; 2021 Aug; 30(8):837-855. PubMed ID: 34171206
[No Abstract] [Full Text] [Related]
36. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
37. Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer.
Gombos A; Franzoi MA; Awada A
Expert Opin Investig Drugs; 2019 Jul; 28(7):617-627. PubMed ID: 31230485
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy for advanced, recurrent, and metastatic cervical cancer.
Moore DH
J Natl Compr Canc Netw; 2008 Jan; 6(1):53-7. PubMed ID: 18267059
[TBL] [Abstract][Full Text] [Related]
39. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
Krill LS; Tewari KS
Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
[TBL] [Abstract][Full Text] [Related]
40. Advances in immunotherapy for cervical cancer: recent developments and future directions.
Sherer MV; Kotha NV; Williamson C; Mayadev J
Int J Gynecol Cancer; 2022 Mar; 32(3):281-287. PubMed ID: 35256414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
